GlassScriptPhysician profile
Yu Xie
NPI 1295044808
$3,634.39
in general payments reported to CMS, 2019-2025
23 companies · $625 in 2025
The $625 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,691 · 2020: $367 · 2021: $337 · 2022: $113 · 2023: $27.91 · 2024: $473 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $732.82 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medical Device Business Services, INC. | $715.33 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $521.58 | 2019-2021 | |
| Heartflow, INC. | $413.09 | 2019-2025 | |
| Pfizer INC. | $164.37 | 2019-2025 | |
| Medtronic, INC. | $153.51 | 2025 | Corevalve Evolut R |
| Impulse Dynamics (USA) INC. | $128.88 | 2024 | Optimizer |
| Amgen INC. | $116.37 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $85.58 | 2019-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.13 | 2019-2022 | |
| Irhythm Technologies, INC. | $74.94 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Novartis Pharmaceuticals Corporation | $69.74 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $55.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $48.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $46.60 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragonix Technologies, INC. | $43.88 | 2025 | Sherpapak |
| E.R. Squibb & Sons, L.L.C. | $41.56 | 2024 | Camzyos |
| Cvrx, INC. | $31.86 | 2024 | Barostim Neo System |
| One Lambda, INC. | $28.72 | 2024 | |
| Astellas Pharma US INC | $23.69 | 2019 | |
| Lundbeck LLC | $21.79 | 2019 | |
| Cathworks, INC. | $20.62 | 2020 | |
| Boston Scientific Corporation | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.